**Holista Colltech Limited**
(ASX:HCT / ABN 24 094 515 992)
283 Rokeby Road Subiaco WA 6008
P: +61 412 474 180
W: www.holistaco.com

# Appendix 4C and Activities Report: Improvements in Receipts and Cost Management Amid Progress in Core Divisions

**ASX Announcement**

**31 Oct 2025**

**Highlights**

- **Customer Receipts Maintained** — $1.56 million recorded from normal operations, with an additional $357K received from debt recovery, reflecting improved collections and stable distributor demand.
- **Operating Cashflow** — Net outflow declined to $78K (vs. $241K in 2QFY25), reflecting timing of supplier payments and continued cost discipline.
- **Supplement Division Sustains Growth** — Sales of approximately $1.5 million (+76% QoQ and +6.8% YoY), maintaining momentum after accounting normalisation in the prior quarter.
- **Collagen and Food Ingredients** — Collagen sales remained steady at $33K while food ingredients moderated to $178K due to timing of orders.
- **Operational Focus** — The Group continues to optimise cashflow and cost containment.

---

**Quarterly Update and Commentary**

Holista Colltech Limited (ASX:HCT, “Holista” or “the Group”) presents its quarterly update and Appendix 4C for the three months ended 30 September 2025 (“3QFY25”). The period demonstrated resilient receipts, stronger cashflow discipline and stable performance across key divisions.

**Financial Overview**

Customer receipts rose to $1.92 million (+16% QoQ), including a debt recovery of $357K from long-outstanding accounts (primarily from aged receivables), strengthening overall cash collections.

Operating costs stood at $1.99 million (+5.7% QoQ), reflecting normalised expenditure and several one-off items, including:

- **Recovery of previously held deposit** — $104K from a long-outstanding balance.
- **Legal fees:** $107K relating to the ProImmune legal case.
- **Inventory preparation:** Additional working-capital outlay to prepare stock for 4QFY25.

Net operating cash outflow declined significantly to $78K, compared with $241K in the previous quarter. This improvement reflected timing of supplier payments amid ongoing cost containment initiatives across the Group's operations.




**All sales figures are subject to audit.*

As at 30 September 2025, the Company maintained a cash balance of $52K with $1.1 million in unused credit facilities, providing a total liquidity buffer of approximately $1.16 million.

In accordance with ASX Listing Rule 4.7C, payments of $54K were made to related parties and their associates during the quarter.

**Divisional Performance**

Group sales totalled $1.73 million (+59% QoQ, primarily due to accounting normalisation). Excluding the one-off adjustment in 2QFY25, sales performance would have been broadly in line with the prior quarter.

- **Dietary Supplements Division** — Revenue rose to $1.52 million (+76% QoQ and +6.8% YoY), sustaining robust momentum from Zuellig Pharma and domestic distribution channels.
- **Food Ingredients Division** — $178K (-7% QoQ and +710% YoY), reflecting temporary shifts in order timings, which are expected to recover in 4QFY25.
- **Ovine Collagen Division** — $33K (+5% QoQ and -52% YoY), maintaining steady performance as the Group progresses while preparing for Collie facility rebuild and upgrade.
- **Infection Control / Agriculture Division** — No sales recorded; management continues to monitor market demand and product alignment.

The Group remains focused on sustaining growth of its supplements business, progressing initiatives to commercialise higher-value nano-collagen and strengthening cost efficiency across all segments.




**All sales figures are subject to audit.*

**Investing and Financing Activities**

The Group maintained a prudent approach to investing and financing activities during the quarter:

- **Investing Activities:** Recorded a modest $9K cash outflow, mainly attributable to a fixed deposit placement under existing banking arrangements and minor office equipment replacement.
- **Financing Activities:** Recorded a net cash inflow of $102K, reflecting additional drawdowns from banking facilities and a short-term loan from a director and third party, offset by scheduled loan repayments.

**Corporate Updates**

There were no new board or executive changes during the quarter.

**Legal Update – Proceedings Relating to ProImmune Matter**

This is the update on legal proceedings brought against Holista in the Supreme Court of Western Australia involving The ProImmune Company LLC ("ProImmune") being CIV1440 of 2025:

1. The Court expressed concern that ProImmune's action had been commenced incorrectly in a procedural sense, and, as such, made certain remedial orders which had the effect of deeming that the action had been commenced by writ of summons and also required ProImmune to file certain court documents in order for it to continue to seek to recover the amount of the judgment from US Courts. Consistent with these orders, ProImmune subsequently filed an application for summary judgment, which application Holista is contesting. The hearing of the summary judgment application is listed for hearing on 13 November 2025.

2. Relatedly, prior to ProImmune commencing its action referred to above, on 31 March 2025 Holista filed proceedings in the Supreme Court of Western Australia against ProImmune being CIV1332 of 2025, in which certain allegations are made by Holista against ProImmune and its director Dr Albert Crum, that arise, out of or are otherwise related to, the facts, matters and circumstances that are the subject of the ProImmune's action (CIV1440 of 2025).

3. New legal representation has been appointed to act for Holista in relation to both above mentioned proceedings.

4. The outcomes of these proceedings (including whether they are consolidated into one proceeding) remain uncertain and may have material implications for the Company, including but not limited to if summary judgment is granted in CIV1440 of 2025.

This announcement has been approved by the Board of Directors.

**-ENDS-**

**About Holista Colltech Limited**

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

# Appendix 4C

# Quarterly cash flow report for entities subject to Listing Rule 4.7B

| Name of entity | |
|---|---|
| **HOLISTA COLLTECH LIMITED (ASX: HCT)** | |
| ABN | Quarter ended ("current quarter") |
| **24 094 515 992** | **30 September 2025** |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (9 months) $A'000 |
|---|---|---|---|
| **1.** | **Cash flows from operating activities** | | |
| 1.1 | Receipts from customers | 1,918 | 5,482 |
| 1.2 | Payments for: | | |
| | (a) research and development | (8) | (28) |
| | (b) product manufacturing and operating costs | (949) | (2,996) |
| | (c) advertising and marketing | (332) | (914) |
| | (d) leased assets | - | - |
| | (e) staff costs | (434) | (1,471) |
| | (f) administration and corporate costs | (211) | (573) |
| 1.3 | Dividends received (see note 3) | - | - |
| 1.4 | Interest received | - | 1 |
| 1.5 | Interest and other costs of finance paid | (23) | (81) |
| 1.6 | Income taxes paid | (39) | (104) |
| 1.7 | Government grants and tax incentives | - | - |
| 1.8 | Other (ASIC Penalty) | - | (900) |
| **1.9** | **Net cash from / (used in) operating activities** | **(78)** | **(1,584)** |
| | | | |
| **2.** | **Cash flows from investing activities** | | |
| 2.1 | Payments to acquire or for: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | (2) | (8) |
| | (d) investments | (7) | (30) |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (9 months) $A'000 |
|---|---|---|---|
| 2.2 | Proceeds from the disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | - |
| | (d) Investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| **2.6** | **Net cash from / (used in) investing activities** | **(9)** | **(38)** |
| | | | |
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | - |
| 3.2 | Proceeds from issue of convertible debt securities | - | 1,552 |
| 3.3 | Proceeds from exercise of share options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | - |
| 3.5 | Proceeds from borrowings | 1,561 | 4,869 |
| 3.6 | Repayment of borrowings | (1,459) | (4,754) |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (provide details if material) | - | - |
| **3.10** | **Net cash from / (used in) financing activities** | **102** | **1,667** |
| | | | |
| **4.** | **Net increase / (decrease) in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 42 | 22 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (78) | (1,584) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (9) | (38) |
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 102 | 1,667 |
| 4.5 | Effect of movement in exchange rates on cash held | (5) | (15) |
| **4.6** | **Cash and cash equivalents at end of period** | **52** | **52** |

**Forex adjustment

| **5.** | **Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | **Current quarter $A'000** | **Previous quarter $A'000** |
|---|---|---|---|
| 5.1 | Bank balances | 52 | 42 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (Restricted Cash) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **52** | **42** |

| **6.** | **Payments to related parties of the entity and their associates** | **Current quarter $A'000** |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 54 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

Fees include Salaries, Director Fees and Consulting Fees to Executive Director and Non-Executive Directors

| 7. | **Financing facilities**<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | **Total facility amount at quarter end $A'000** | **Amount drawn at quarter end $A'000** |
|---|---|---|---|
| 7.1 | Loan facilities | 442 | 442 |
| 7.2 | Credit standby arrangements | 2,335 | 1,232 |
| 7.3 | Other (please specify) | | |
| 7.4 | **Total financing facilities** | **2,777** | **1,674** |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | **1,103** |

7.6 Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

**Summary of Banking Facilities:**

**Bank Loan Facility 1:**

**Parties:** CIMB Islamic Bank Berhad Malaysia (**Banker**), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Collect Ltd) (**Borrower**).

**i) Loan Facility 1**

**Term Loan**

**Principal Amount:** MYR 1.4M / approximately A$503k

**Remaining Payable as at 30 September 2025:** MYR 1.14M / approximately A$409k

**Term:** Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of $3,127 (2024: $3,186) and ending in 200 months on 4 October 2040.

**Interest Rate:** 3.74% per annum (2024: 3.74%).

**ii) Credit Standby Arrangement 1**

Trade Financing and Banker Acceptances bears interest of 4.83% per annum (2024: 5.07%).

**Total Amount at Quarter End:** MYR 2M / Approximately A$718k

**Total Utilised at Quarter End:** MYR 1.978K / Approximately A$711k

Bank Loan Facility 1 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Facility agreement;
- First party assignment over the office lots of the Company;
- Deed of assignment of rental proceeds;
- Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and
- Guarantee by a director of the Company.

Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi Currency Trade Financing-i**", to facilitate local and export sales of the Borrower; and
- "**Bank Guarantee**", for issuance of financial, performance and security bonds to government and private entities, in relation to business.

**Bank Loan Facility 2:**

**Parties:** CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

**i) Loan Facility 2**

**Term Loan**

**Principal Amount:** MYR 200K / approximately A$72K.

**Amount Remaining as at 30 September 2025**: MYR 90k / approximately A$32k

**Term:** Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of A$1,423 (2024: A$1,413) and ending in 44 months on 4 November 2027.

**Interest Rate:** 6.60% per annum (2024: 6.60%).

**ii) Credit Standby Arrangement 2**

**Trade Financing and Banker Acceptance** bears interest of 4.83% per annum (2024: 5.09%).

**Total Amount at Quarter End:** MYR 1.5M / Approximately A$539k

**Total Utilised at Quarter End:** MYR 1.451K / Approximately A$521k

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi Currency Trade Financing-i**", to facilitate local and export sales of the Borrower;
- "**Documentary Credit-i**", to facilitate local and import purchases of the Borrower;
- "**Accepted Bills-i 2**", to facilitate local and import purchases of the Borrower; and
- "**Multi Currency Trade Financing-i 2**", to facilitate local and import purchases of the Borrower.

**Bank Loan Facility 3:**

**Parties:** CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

**i) Credit Standby Arrangement 3**

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

**Total Amount at Quarter End:** MYR 3.0M / Approximately A$1,078k

**Total Utilised at Quarter End:** MYR nil / Approximately A$ nil

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- "**Accepted Bills-i**", to facilitate local and export sales of the Borrower;
- "**Multi-Currency Trade Financing-i**", to facilitate local and export sales of the Borrower;
- "**Documentary Credit-i**", to facilitate local and import purchases of the Borrower;
- "**Accepted Bills-i 2**", to facilitate local and import purchases of the Borrower; and
- "**Multi-Currency Trade Financing-i 2**", to facilitate local and import purchases of the Borrower.

| 8. | Estimated cash available for future operating activities | $A'000 |
|---|---|---|
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | (78) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 52 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | 1,103 |
| 8.4 | Total available funding (item 8.2 + item 8.3) | **1,155** |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | **14.8** |
| | *Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.* | |
| 8.6 | If item 8.5 is less than 2 quarters, please provide answers to the following questions: | |
| | 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? | |
| | Answer: N/A | |
| | 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? | |
| | Answer: N/A | |
| | 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? | |
| | Answer: N/A | |
| | *Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.* | |

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

**Date:** **31 October 2025**

**Authorised by:** The Board
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.